1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
J Hepatol 2018;69:406–460.
2. Jalan R, Dabos K, Redhead DN, Lee A, Hayes PC. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.
J Hepatol 1997;27:928–933.
3. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options.
Blood Purif 2002;20:252–261.
4. Arroyo V, Moreau R, Kamath PS, et al. Acute-on-chronic liver failure in cirrhosis.
Nat Rev Dis Primers 2016;2:16041.
5. Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: definitions, pathophysiology and principles of treatment.
JHEP Rep 2020;3:100176.
6. Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure.
N Engl J Med 2020;382:2137–2145.
7. Amin A, Mookerjee RP. Acute-on-chronic liver failure: definition, prognosis and management.
Frontline Gastroenterol 2019;11:458–467.
8. Bajaj JS, O’Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines.
Am J Gastroenterol 2022;117:225–252.
10. Asrani SK, Simonetto DA, Kamath PS. Acute-on-chronic liver failure.
Clin Gastroenterol Hepatol 2015;13:2128–2139.
11. Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States.
Hepatology 2016;64:2165–2172.
12. Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update.
Hepatol Int 2019;13:353–390.
13. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.
J Hepatol 2014;61:1038–1047.
14. Bajaj JS, O’Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures.
Hepatology 2014;60:250–256.
15. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
Gastroenterology 2013;144:1426–1437.
16. Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?
Kidney Int 2017;92:1058–1070.
17. Angeli P, Rodríguez E, Piano S, et al. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.
Gut 2015;64:1616–1622.
19. Méndez-Guerrero O, Calle-Rodas DA, Cervantes-Alvarez E, et al. Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit.
Ann Hepatol 2021;22:100270.
20. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.
J Hepatol 2015;62:968–974.
21. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury.
Nephron Clin Pract 2012;120:c179–c184.
23. Yoo JJ, Kim SG, Kim YS, et al. Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
J Hepatol 2019;70:847–854.
24. Lee HA, Seo YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis.
Clin Mol Hepatol 2022;28:31–46.
25. Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.
J Hepatol 2013;59:474–481.
26. Tandon P, James MT, Abraldes JG, Karvellas CJ, Ye F, Pannu N. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study.
PLoS One 2016;11:e0160394.
28. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
J Hepatol 2011;55:315–321.
29. Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Milionis HJ. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
Eur J Gastroenterol Hepatol 2019;31:1292–1294.
30. Yoo JJ, Kwon JH, Kim YS, et al. The role of urinary N-acetyl-β-d-glucosaminidase in cirrhotic patients with acute kidney injury: multicenter, prospective cohort study.
J Clin Med 2021;10:4328.
31. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document.
J Hepatol 2019;71:811–822.
32. Kim TY, Song DS, Kim HY, et al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition.
PLoS One 2016;11:e0146745.
33. Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure.
Hepatol Int 2016;10:245–257.
34. Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis.
World J Gastroenterol 2018;24:2300–2310.
35. Maiwall R, Kumar S, Chandel SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis.
Hepatol Int 2015;9:627–639.
36. Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
J Hepatol 2021;74:1117–1131.
37. Solé C, Guilly S, Da Silva K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis.
Gastroenterology 2021;160:206–218.
38. Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome.
Gastroenterol Rep (Oxf) 2017;5:127–137.
39. Cullaro G, Kanduri SR, Velez JC. Acute kidney injury in patients with liver disease.
Clin J Am Soc Nephrol 2022;17:1674–1684.
40. Saini M, Kataruka M, Gogoi B, Sharma V, Madan GS, Sood C. Incidence of renal tract abnormalities on ultrasonography in patients with spinal cord injury: a retrospective pilot study of a military cohort undergoing long-term institutional rehabilitation.
Asian Spine J 2022;16:204–211.
41. Gawande A, Gupta GK, Gupta A, et al. Acute-on-chronic liver failure: etiology of chronic and acute precipitating factors and their effect on mortality.
J Clin Exp Hepatol 2019;9:699–703.
42. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update.
Gut 2017;66:541–553.
43. Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.
Hepatol Int 2014;8:453–471.
44. Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management.
Nat Rev Gastroenterol Hepatol 2016;13:131–149.
45. Kim DJ. Acute-on-chronic liver failure.
Korean J Med 2017;92:118–123.
46. Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients.
Am J Gastroenterol 2019;114:929–937.
47. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant mechanisms in renal injury and disease.
Antioxid Redox Signal 2016;25:119–146.
48. Blasco-Algora S, Masegosa-Ataz J, Gutiérrez-García ML, Alonso-López S, Fernández-Rodríguez CM. Acute-on-chronic liver failure: pathogenesis, prognostic factors and management.
World J Gastroenterol 2015;21:12125–12140.
49. Qiang R, Liu XZ, Xu JC. The immune pathogenesis of acute-on-chronic liver failure and the danger hypothesis.
Front Immunol 2022;13:935160.
50. Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function.
Semin Liver Dis 2016;36:133–140.
51. Martin-Mateos R, Alvarez-Mon M, Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: it takes two to tango.
Front Immunol 2019;10:973.
53. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis.
J Hepatol 2014;60:197–209.
54. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications.
Liver Int 2013;33:31–39.
55. Dunn W, Shah VH. Pathogenesis of alcoholic liver disease.
Clin Liver Dis 2016;20:445–456.
56. Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management.
Alcohol Res 2017;38:147–161.
58. Han SJ, Lee HT. Mechanisms and therapeutic targets of ischemic acute kidney injury.
Kidney Res Clin Pract 2019;38:427–440.
59. Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes.
Clin Biochem Rev 2016;37:85–98.
60. Somagutta MR, Jain MS, Pormento MK, et al. Bile cast nephropathy: a comprehensive review.
Cureus 2022;14:e23606.
61. Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.
Hepatology 2017;66:1232–1241.
62. Wan ZH, Wang JJ, You SL, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.
World J Gastroenterol 2013;19:9432–9438.
63. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.
Hepatology 2014;60:622–632.
64. Jindal A, Bhadoria AS, Maiwall R, Sarin SK. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure.
Liver Int 2016;36:59–67.
65. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis.
Hepatology 2008;48:2064–2077.
66. Russ KB, Stevens TM, Singal AK. Acute kidney injury in patients with cirrhosis.
J Clin Transl Hepatol 2015;3:195–204.
67. Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis.
World J Gastroenterol 2009;15:1459–1464.
68. Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis.
Gastroenterology 2018;155:1816–1827.
69. Sidhu GS, Go A, Attar BM, Mutneja HR, Arora S, Patel SA. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review.
BMJ Open Gastroenterol 2017;4:e000154.
70. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial.
Hepatology 2004;39:746–753.
71. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients.
Gut 2000;46 Suppl 3-4:III1–III15.
72. Fernández J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: good and bad.
Hepatology 2016;63:2019–2031.
73. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Gastroenterology 2007;133:818–824.
74. Kulkarni AV, Kumar P, Sharma M, et al. Pathophysiology and prevention of paracentesis-induced circulatory dysfunction: a concise review.
J Clin Transl Hepatol 2020;8:42–48.
75. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med 1999;341:403–409.
76. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Lancet 2018;391:2417–2429.
77. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.
N Engl J Med 2011;365:1781–1789.
78. Kedarisetty CK, Anand L, Bhardwaj A, et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
Gastroenterology 2015;148:1362–1370.
79. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis.
N Engl J Med 2015;372:1619–1628.
80. Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis.
J Hepatol 2016;65:809–824.
81. Fagundes C, Pépin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.
J Hepatol 2012;57:267–273.
83. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Hepatology 2010;51:219–226.
84. Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival.
J Hepatol 2020;72:481–488.
85. Trebicka J, Sundaram V, Moreau R, Jalan R, Arroyo V. Liver transplantation for acute-on-chronic liver failure: science or fiction?
Liver Transpl 2020;26:906–915.
86. Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation.
Gastroenterology 2019;156:1381–1391.
88. Xu X, Ling Q, Zhang M, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience.
Transplantation 2009;87:1514–1519.
89. Wong F, Leung W, Al Beshir M, Marquez M, Renner EL. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.
Liver Transpl 2015;21:300–307.
90. Nadim MK, Kellum JA, Davenport A, et al. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
Crit Care 2012;16:R23.
92. Altshuler PJ, Shah AP, Frank AM, et al. Simultaneous liver kidney allocation policy and the Safety Net: an early examination of utilization and outcomes in the United States.
Transpl Int 2021;34:1052–1064.
93. Nagai S, Suzuki Y, Kitajima T, et al. Paradigm change in liver transplantation practice after the implementation of the liver-kidney allocation policy.
Liver Transpl 2021;27:1563–1576.
94. Del Risco-Zevallos J, Andújar AM, Piñeiro G, et al. Management of acute renal replacement therapy in critically ill cirrhotic patients.
Clin Kidney J 2022;15:1060–1070.
95. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients.
J Hepatol 2012;56 Suppl 1:S13–S24.
96. Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective.
J Hepatol 2016;64:717–735.
97. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure.
Kidney Int Suppl 1993;41:S245–S251.
98. Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ; US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.
Hepatology 2018;67:711–720.
100. Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure.
Curr Opin Crit Care 2019;25:187–191.